Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
In this article:
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
Advertisement
Recommended Stories
Forget Nvidia, These Unstoppable Stocks Are Better Buys
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
Motley Fool•1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
Motley Fool•FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves
Benzinga•How 'Megatrends' Like Weight-Loss Drugs And Smartwatches Are Bolstering ResMed
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
Investor's Business Daily•Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks
Some companies, however, reported a market capitalisation decline, including Gilead Sciences and Roche.
Pharmaceutical Technology•Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
Investor's Business Daily•Worried About Assisted Living Costs? Here Are Your Options
Long-term care in residential facilities like nursing homes is a financial challenge for many. When dealing with a loved one who is disabled, elderly or ill, families often try every other kind of long-term care facility first. Because nursing homes … Continue reading → The post Nursing Home Costs: How You Can Cover Them appeared first on SmartAsset Blog.
SmartAsset•Bernie Sanders slams pharma giant for ‘outrageously high’ drug prices, threatening the ‘entire health care system’
Patients in the U.S. pay up to 15 times more for these drugs compared to in Canada, Europe or Japan.
Moneywise•Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
Zacks•Pfizer Receives FDA Approval for Bleeding Disorder Treatment
Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment—the drug-maker’s first gene therapy to be approved in the U.S. The treatment, Beqvez, is for adults with moderate to severe hemophilia B—a disorder that prevents normal blood clotting—and will be available by prescription to eligible patients this quarter, according to the company. “Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular FIX infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues,” said Adam Cuker, director of University of Pennsylvania’s Comprehensive Hemophilia and Thrombosis Program.
Barrons.com•